Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Ann Oncol ; 27(10): 1860-6, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27672107

RESUMEN

BACKGROUND: Estrogen receptor-positive (ER+) breast cancers (BCs) constitute the most frequent BC subtype. The molecular landscape of ER+ relapsed disease is not well characterized. In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy. MATERIALS AND METHODS: A total of 182 ER+ metastatic BC patients with long-term follow-up were identified from a single institution. P tumor tissue was available for all patients, with 88 having matched M material. According to the availability of tumor material, samples were characterized using a 120 mutational hotspot qPCR, a 29 gene copy number aberrations (CNA) and a 400 gene expression panels. ESR1 mutations were assayed by droplet digital PCR. Molecular alterations were correlated with overall survival (OS) using the Cox proportional hazards regression models. RESULTS: The median follow-up was 6.4 years (range 0.5-26.6 years). Genomic analysis of P tumors revealed somatic mutations in PIK3CA, KRAS, AKT1, FGFR3, HRAS and BRAF at frequencies of 41%, 6%, 5%, 2%, 1% and 2%, respectively, and CN amplification of CCND1, ZNF703, FGFR1, RSF1 and PAK1 at 23%, 19%, 17%, 12% and 11%, respectively. Mutations and CN amplifications were largely concordant between P and matched M (>84%). ESR1 mutations were found in 10.8% of the M but none of the P. Thirteen genes, among which ESR1, FOXA1, and HIF1A, showed significant differential expression between P and M. In P, the differential expression of 18 genes, among which IDO1, was significantly associated with OS (FDR < 0.1). CONCLUSIONS: Despite the large concordance between P and matched M for the evaluated molecular alterations, potential actionable targets such as ESR1 mutations were found only in M. This supports the importance of characterizing the M disease. Other targets we identified, such as HIF1A and IDO1, warrant further investigation in this patient population.


Asunto(s)
Neoplasias de la Mama/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Indolamina-Pirrol 2,3,-Dioxigenasa/genética , Receptores de Estrógenos/genética , Neoplasias de la Mama/patología , Variaciones en el Número de Copia de ADN/genética , Supervivencia sin Enfermedad , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Mutación , Metástasis de la Neoplasia , Proteínas de Neoplasias/genética , Transcriptoma/genética
2.
Br J Cancer ; 108(8): 1641-7, 2013 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-23519055

RESUMEN

BACKGROUND: Clinical outcome of high-risk melanoma patients is not reliably predicted from histopathological analyses of primary tumours and is often adjusted during disease progression. Our study aimed at extending our previous findings in skin metastases to evaluate the prognostic value of tyrosinase-related protein 1 (TYRP1) in lymph node metastases of stages III and IV melanoma patients. METHODS: TYRP1 mRNA expression in 104 lymph node metastases was quantified by real-time PCR and normalised to S100 calcium-binding protein B (S100B) mRNA expression to correct for tumour load. TYRP1/S100B ratios were calculated and median was used as cutoff value. TYRP1/S100B mRNA values were correlated to clinical follow-up and histopathological characteristics of the primary lesion. RESULTS: A high TYRP1/S100B mRNA ratio significantly correlated with reduced disease-free (DFS) and overall survival (OS; Cox regression analysis, P=0.005 and 0.01, respectively), increased Breslow thickness (Spearman's rho test, P<0.001) and the presence of ulceration (Mann-Whitney test, P=0.02) of the primaries. Moreover, high TYRP1/S100B was of better prognostic value (lower P-value) for OS than Breslow thickness and ulceration. Finally, it was well conserved during disease progression with respect to high/low TYRP1 groups. CONCLUSION: High TYRP1/S100B mRNA expression in lymph node metastases from melanoma patients is associated with unfavourable clinical outcome. Its evaluation in lymph node metastases may refine initial prognosis for metastatic patients, may define prognosis for those with unknown or non-evaluable primary lesions and may allow different management of the two groups of patients.


Asunto(s)
Ganglios Linfáticos/metabolismo , Melanoma/genética , Glicoproteínas de Membrana/genética , Oxidorreductasas/genética , ARN Mensajero/biosíntesis , Adolescente , Adulto , Anciano , Biomarcadores de Tumor/biosíntesis , Biomarcadores de Tumor/genética , Supervivencia sin Enfermedad , Femenino , Humanos , Ganglios Linfáticos/patología , Metástasis Linfática , Masculino , Melanoma/enzimología , Melanoma/patología , Glicoproteínas de Membrana/biosíntesis , Persona de Mediana Edad , Factores de Crecimiento Nervioso/biosíntesis , Factores de Crecimiento Nervioso/genética , Oxidorreductasas/biosíntesis , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Factores de Riesgo , Subunidad beta de la Proteína de Unión al Calcio S100 , Proteínas S100/biosíntesis , Proteínas S100/genética , Tasa de Supervivencia , Adulto Joven
3.
Bone ; 35(2): 479-88, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15268900

RESUMEN

Skeleton is the most common organ targeted by breast cancer cells, especially from estrogen receptor alpha (ER)-positive neoplasms. Metastatic cells can stimulate directly or indirectly osteoclast-mediated bone resorption. Tumor-induced osteolysis is often extensive and leads to the release of large quantities of calcium. Metastatic cancer cells can be thus exposed to high calcium concentrations (40 mM has been reported at the resorption site). However, the effects of Ca2+ on breast cancer cells have been minimally examined. We showed that 20-mM extracellular Ca2+ induced a downregulation of ER protein in MCF-7 cells and caused ER-mediated transactivation of a reporter gene by 55 +/- 10% (mean +/- SD) in MVLN cells (MCF-7 cells stably transfected with ERE and luciferase reporter gene). Moreover, 3 mM Ca2+ increased progesterone receptor (PgR) expression by 45 +/- 8%. Mg2+ tested at up to 20 mM did not exert any effects, while 17beta-estradiol downregulated ER, transactivated the reporter gene, and enhanced PgR expression. The pure antiestrogen ICI 182,780 was able to abrogate the transactivation of the reporter gene and the increase in PgR levels induced by Ca2+, indicating that Ca2+ may exert a weak and specific estrogenic effect in MCF-7 cells. Ca2+ effects on ER probably start at the cell membrane level since a large Ca2+ influx caused by the ionophore A23187 failed to activate ER. We have thus studied the involvement of the membrane calcium-sensing receptor (CaR) that is known to be expressed notably in MCF-7 cells. We first tested the effects of a specific activator of CaR. Exposure to 10(-4) M calcimimetic NPS R-467 mirrored the changes observed with extracellular Ca2+ by inducing a marked decrease in ER protein levels, increasing the transcriptional activity of ER (67 +/- 12%) and stimulating PgR expression (41 +/- 4%). As expected, the NPS S-467 isomer was less effective. Furthermore, a highly selective CaR antagonist partly suppressed the downregulation of ER as well as transactivation of the reporter gene induced by Ca(2+). Our results suggest that the effects of extracellular Ca2+ on ER expression and activity are mediated, at least in part, by the CaR. In summary, calcium released during the process of metastatic bone destruction could modulate the functions of the estrogen receptor, a key receptor involved in breast cancer cells growth and function, and thus participate in the pathogenesis of tumor-induced osteolysis.


Asunto(s)
Neoplasias de la Mama/patología , Calcio/fisiología , Regulación hacia Abajo/fisiología , Estradiol/análogos & derivados , Receptor alfa de Estrógeno/fisiología , Receptores Sensibles al Calcio/fisiología , Transcripción Genética/fisiología , Calcimicina/farmacología , Línea Celular Tumoral , Estradiol/farmacología , Receptor alfa de Estrógeno/efectos de los fármacos , Fulvestrant , Humanos , Técnicas para Inmunoenzimas
4.
Mol Cell Endocrinol ; 164(1-2): 19-29, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11026554

RESUMEN

In MCF-7 cells, estradiol (E2) and pure antiestrogens (AEs) decrease estrogen receptor alpha (ER) levels, while AEs with partial estrogenic activity lead to ER alpha accumulation. Using immunocytochemistry, we found that cells pre-exposed to one of such ligands, when plated with untreated cells, led to similar ER changes in the latter. Conditioned media (CMs) prepared from stimulated cells displayed identical regulatory effects even after strong dilution; they also modulated ERE-dependent transcriptional activity. Evaluation of residual ligand concentrations in CMs rejected the possibility of a major interference of the former. Cycloheximide, which inhibits E2-induced down-regulation, failed to block the influence of CM(E2) in agreement with this view. DCC-treatment of CMs abrogated their effects, suggesting the release of hydrophobic compound(s) which regulate ER and/or amplify the effect of extremely low amounts of residual ligands. Such a release appears independent of ER since CMs from MDA-MB-231 cells (ER-negative) were effective as their autologous media on MCF-7 cells.


Asunto(s)
Receptores de Estrógenos/fisiología , Transducción de Señal , Animales , Línea Celular , Medios de Cultivo Condicionados , Estradiol/farmacología , Estradiol/fisiología , Ligandos , Receptores de Estrógenos/agonistas , Receptores de Estrógenos/antagonistas & inhibidores
5.
J Steroid Biochem Mol Biol ; 57(3-4): 203-13, 1996 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8645630

RESUMEN

Effect of estrogens and antiestrogens (AEs) on estrogen receptor (ER) half-life was analyzed in MCF-7 cells by assessing its progressive disappearance after covalent labeling in situ with [3H]tamoxifen aziridine ([3H]TAZ). Cells were incubated for 1 h with 20 nM [3H]TAZ either in the absence or presence of a 500-fold excess of unlabeled estradiol (E2) (non-specific binding). The entire ER population was labeled by this method as established by subsequent incubation of the cells with [125I]E2. [3H]TAZ labeled cells were maintained in culture for additional 5 h in the absence (control) or presence of increasing amounts (0.1 nM - 1 microM) of either a given estrogen (E2, estrone, diethylstilbestrol, bisphenol), a pure AE (RU 58 668, ICI 164 384) or an AE with residual estrogenic activity (RU 39 411, 4-hydroxytamoxifen, keoxifene). The progressive disappearance of nuclear and cytosolic [3H]TAZ-ER complex during 5 h incubation were assessed by their immunoprecipitation with anti-ER monoclonal antibody (H 222) followed by scintillation counting or SDS-PAGE and fluorography. Fading of labeled receptors was extremely slow (approximately 10% loss after 6 h) in absence of any hormone/antihormone indicating a long half-life of the [3H]TAZ-ER complex. Addition of estrogens as well as pure AEs led to a dramatic reduction of the half-life while AEs with residual estrogenic activity were extremely less efficient in this regard providing an explanation for the ability of latter compounds to up-regulate the receptor since they do not affect ER mRNA synthesis and stability. Receptor disappearance induced by estrogens was closely related to their binding affinity for ER. Newly synthesized ER emerged during the treatment with hormones or antihormones seems to be implicated in the phenomenon since [3H]TAZ was covalently bound and could, therefore, not be displaced by these compounds. Induction of synthesis of a short half-life peptide(s) with degradative activity was demonstrated by addition of cycloheximide or puromycine (both at 50 microM) which completely blocked ER disappearance. The fact that no cleavage products of ER were detected by SDS-PAGE suggested a lysosomial hydrolysis. Hence, hormonal modulation of only a part of ERs may down-regulate their total population until it reaches the steady-state level.


Asunto(s)
Neoplasias de la Mama/metabolismo , Antagonistas de Estrógenos/farmacología , Estrógenos/farmacología , Receptores de Estrógenos/metabolismo , Núcleo Celular/química , Cicloheximida/farmacología , Citosol/química , Estradiol/metabolismo , Semivida , Humanos , Indicadores y Reactivos , Peso Molecular , Inhibidores de la Síntesis de la Proteína/farmacología , Puromicina/farmacología , ARN Mensajero/biosíntesis , ARN Mensajero/metabolismo , Receptores de Estrógenos/análisis , Receptores de Estrógenos/biosíntesis , Receptores de Estrógenos/química , Tamoxifeno/análogos & derivados , Células Tumorales Cultivadas , Regulación hacia Arriba/efectos de los fármacos
6.
Steroids ; 65(12): 903-13, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11077089

RESUMEN

In MCF-7 breast cancer cells, hydroxytamoxifen (OH-Tam) up-regulates the estrogen receptor (ER) in a form unable to bind [(3)H]estradiol (E(2)). We show here that this property is not restricted to this antiestrogen. [(3)H]E(2) binding assays (whole cell assays, DCC assays on cell extracts) and enzyme immunoassays (Abbott) performed in parallel, establish the permanent presence of such unusual ERs in the absence of any exposure of the cells to a ligand. E(2) and the pure antiestrogen RU 58 668, which down-regulate ER, also decrease [(3)H]E(2) binding. In control cells, these ERs represent about the half of the whole receptor population; they also display a tendency to stabilize within the cell nucleus. Loss of E(2) binding ability appears irreversible, since we failed to label receptor accumulated under OH-Tam with [(3)H]E(2) or [(3)H]tamoxifen aziridine (TAZ). Cycloheximide (CHX), which blocks E(2)-induced down regulation of ER, failed to stabilize [(3)H]E(2) binding (whole cell assay) after an [(3)H]E(2) pulse (1 h), confirming that regulation of E(2) binding and peptide level are related to different regulatory mechanisms. Loss of binding ability could not be ascribed to any ER cleavage as demonstrated by Western blotting with a panel of ER antibodies raised against its various domains (67 kDa ER solely detected). We propose that loss of E(2) binding ability is related to the aging process of the receptor, i.e. it is progressively converted to a form devoted to degradation after it has accomplished its physiological role. Ligands may favor (E(2), RU 58 668) or impede (OH-Tam) this elimination process.


Asunto(s)
Neoplasias de la Mama/patología , Estradiol/análogos & derivados , Receptores de Estrógenos/metabolismo , Antineoplásicos Hormonales/farmacología , Western Blotting , Neoplasias de la Mama/química , Núcleo Celular/química , Cicloheximida/farmacología , Citosol/química , Regulación hacia Abajo/efectos de los fármacos , Estradiol/metabolismo , Estradiol/farmacocinética , Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Moduladores de los Receptores de Estrógeno/farmacología , Femenino , Humanos , Ligandos , Unión Proteica , Inhibidores de la Síntesis de la Proteína/farmacología , Receptores de Estrógenos/química , Receptores de Estrógenos/efectos de los fármacos , Tamoxifeno/farmacología , Factores de Tiempo , Tritio , Células Tumorales Cultivadas , Regulación hacia Arriba
7.
Ann Clin Lab Sci ; 25(2): 179-84, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7785966

RESUMEN

Two cases are described to illustrate the use of the myoglobin clearance rate as a predictor of acute renal failure (ARF). Both patients suffered extensive skeletal muscle injury characterized by high total creatinine kinase and urine myoglobin. In the first case, a high myoglobin clearance at admission (27 mL/min) was accompanied by normal serum creatinine and creatinine clearances. This patient recovered without renal complications. The second case also had normal serum creatinine and creatinine clearances at the initial presentation of symptoms, but was accompanied by a very low myoglobin clearance (0.64 mL/min). Within 48 h, this patient developed acute renal failure, with creatinine rising from 1.5 to 5.8 mg/dL, and creatinine clearance dropping from 270 to 2.8 mL/min. Because myoglobin has been recognized as a cause of ARF, these cases help illustrate how the myoglobin clearance rate might be used in evaluating patients with rhabdomyolysis for the development ARF.


Asunto(s)
Lesión Renal Aguda/etiología , Mioglobina/sangre , Rabdomiólisis/complicaciones , Adulto , Anciano , Humanos , Masculino , Tasa de Depuración Metabólica , Mioglobinuria , Valor Predictivo de las Pruebas
9.
Breast Cancer Res Treat ; 93(3): 207-15, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16136271

RESUMEN

PURPOSE: Estrogen receptor alpha (ERalpha) plays a major role in breast cancer development. It acts as ligand-inducible transcription factor which determines growth, survival and differentiation of breast cancer cells. The aim of this study is to evaluate the potential interference between radiotherapy and estrogen receptor responsiveness. Materials and methods. The effect of ionizing radiation was assessed on the estrogen receptor alpha status, growth (proliferation and apoptosis) and sensitivity of MCF-7 breast cancer cells to estrogenic (17beta-estradiol (E2)), selective estrogen receptor modulator (SERM) and anti-estrogenic compounds. Results. We have observed a ligand-independent decrease in ERalpha expression after radiation, resulting from a specific reduction in mRNA level and protein synthesis. This ERalpha disappearance occurred 72 h post-irradiation at 8 Gy and decreased the transcriptional activity in ERalpha of these cells. On the other hand, E2 impedes the growth inhibitory effects (essentially on proliferation) of ionizing radiation in MCF-7 cells, which potentially decreases radiosensitivity of these cells. This effect was totally blocked by SERM and anti-estrogenic treatments. Moreover, this growth effect of concurrent anti-estrogenic drugs and ionizing radiation appeared to be strongly synergistic. CONCLUSIONS: This study may increase general comprehension of ERalpha modulation by radiotherapy and improve adjuvant therapeutic approaches based on co-administration of radiation and endocrine therapy.


Asunto(s)
Antineoplásicos Hormonales/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Receptor alfa de Estrógeno/efectos de los fármacos , Receptor alfa de Estrógeno/efectos de la radiación , Análisis de Varianza , Apoptosis/efectos de la radiación , Ciclo Celular/efectos de la radiación , Relación Dosis-Respuesta a Droga , Relación Dosis-Respuesta en la Radiación , Interacciones Farmacológicas , Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Receptor alfa de Estrógeno/biosíntesis , Humanos , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Células Tumorales Cultivadas
10.
Anal Chem ; 65(14): 1903-9, 1993 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-8368537

RESUMEN

This paper describes an extensive kinetic study of the reactions involved in the determination of acetoacetate in body fluids. It is concluded that acetoacetate reacts with glycine to produce an imine intermediate that tautomerizes to an enamine. It is also concluded that nitroprusside reacts with the imine intermediate to produce an unstable product with an absorption maximum near 540 nm. This product decays slowly to produce a stable product with an absorption maximum near 393 nm. A proposed reaction pathway is used to develop kinetic equations, rate constants, equilibrium constants, and molar absorptivity of the unstable product that permit quantitative prediction of the kinetic behavior for a wide range of reactant concentrations.


Asunto(s)
Acetoacetatos/química , Glicina/química , Nitroprusiato/química , Cinética , Espectrofotometría Ultravioleta
11.
Int J Cancer ; 78(6): 760-5, 1998 Dec 09.
Artículo en Inglés | MEDLINE | ID: mdl-9833770

RESUMEN

Data from immunocytochemical assessment of estrogen receptor (ER) regulation in MCF-7 cells under estrogenic and anti-estrogenic stimulation were compared with those obtained by enzyme immunoassay (Abbott ER-EIA). Similar trends were observed, although ER level variations were less marked when assessed immunocytochemically. We confirmed reports of ER disappearance in the presence of estrogens (Es; E2 and DES) and pure anti-estrogens (AEs; RU 58,668 and ICI 164,384) as well as its increase with partial AEs (4-OH-TAM and RU 39,119). E2-induced ER down-regulation was partly blocked by actinomycin D (AMD), okadaic acid (OK) and cycloheximide (CHX) when assessed by these 2 methods. Down-regulation by pure AEs was not impeded by CHX, indicating that they operate differently from Es (i.e., transformation of ER to a form sensitive to constitutive degradation activity). In situ pre-labeling of the cells with [3H]TAZ indicated that all investigated ligands eliminate pre-existing ER through binding to newly synthetized receptors, since [3H]TAZ co-valently associates with ER; E2 and RU 58,668 were more effective than 4-OH-TAM in this regard. CHX blocked ER disappearance even in the presence of pure AEs, which is in contrast to the data established with cells not pre-exposed to [3H]TAZ. Nuclear location of [3H]TAZ-ER complexes may explain this discrepancy, since pure AE-ER complexes were reported to be incapable of nuclear translocation.


Asunto(s)
Neoplasias de la Mama/metabolismo , Antagonistas de Estrógenos/farmacología , Estrógenos/farmacología , Técnicas para Inmunoenzimas , Inmunohistoquímica , Receptores de Estrógenos/metabolismo , Cicloheximida/farmacología , Dactinomicina/farmacología , Regulación hacia Abajo , Estradiol/análogos & derivados , Estradiol/farmacología , Humanos , Cinética , Ácido Ocadaico/farmacología , Alcamidas Poliinsaturadas , Tamoxifeno/farmacología , Factores de Tiempo , Células Tumorales Cultivadas
12.
Clin Chem ; 40(5): 796-802, 1994 May.
Artículo en Inglés | MEDLINE | ID: mdl-8174254

RESUMEN

We compared four immunoassays for serum and urine myoglobin. Within-run CVs were 5-13%, with biases seen between assays. Myoglobin was stable for 1 month in serum and 12 days in urine when the pH was adjusted to between 8.0 and 9.5. Hemoglobin caused no interference. We assayed 91 pairs of serum and timed urine specimens from 41 patients admitted for acute trauma or rhabdomyolysis. Most were treated with mannitol and alkalinization. Upon initial presentations, 21 patients with either low serum myoglobin concentrations (< 400 micrograms/L) or high myoglobin clearances (> or = 4 mL/min) had normal creatinine clearances and no clinical evidence of renal disease. The remaining 20 had low myoglobin clearances. Seven were in rhabdomyolysis-induced acute renal failure, or subsequently developed this complication. We suggest that low myoglobin clearance may indicate a high risk for developing renal failure or may be an early marker for kidney dysfunction. Low myoglobin clearance may prove useful in indicating failure of prophylactic treatment to clear myoglobin.


Asunto(s)
Lesión Renal Aguda/metabolismo , Inmunoensayo , Mioglobina/metabolismo , Lesión Renal Aguda/etiología , Estabilidad de Medicamentos , Femenino , Humanos , Concentración de Iones de Hidrógeno , Inmunoensayo/estadística & datos numéricos , Masculino , Manitol/uso terapéutico , Tasa de Depuración Metabólica , Mioglobina/sangre , Mioglobinuria/orina , Control de Calidad , Valores de Referencia , Rabdomiólisis/complicaciones , Rabdomiólisis/metabolismo , Factores de Riesgo , Sensibilidad y Especificidad , Factores de Tiempo , Heridas y Lesiones/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA